WALTHAM, Mass., Nov. 2 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. today announced that it will release its third quarter financial results on Wednesday, November 7 after the market closes. The Company’s management will host the conference call at 4:30 PM EST to review Interleukin’s 2007 third quarter financial results and provide management updates.
Conference Call Details
To access the live call on November 7, 2007 at 4:30 PM EST, dial (800) 366-3964 (domestic) or (303) 205-0055 (international). The call will also be available live via webcast at www.ilgenetics.com.
Replay access of the teleconference will be available for two weeks following the call by calling (800) 405-2236 (domestic) or (303) 590-3000 (international). The passcode for the replay is 11101550. The webcast will be archived following the call at www.ilgenetics.com.
About Interleukin
Interleukin Genetics, Inc. is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin currently offers an array of Nutraceuticals and OTCeuticals, including Ginkoba(R), Ginsana(R) and Venastat(R) which are sold at the nation’s largest food, drug and mass retailers, and has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment. Interleukin is headquartered in Waltham, MA. For more information about Interleukin and its ongoing programs, please visit www.ilgenetics.com.
Forward Looking Statements
Certain statements contained herein are “forward-looking” statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns, our ability to make progress in advancing our core technologies, and our expectations regarding fiscal year 2007 revenues and gross profit margins of our nutritional supplement products. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, our ability to integrate acquired businesses, our ability to maintain relationships with our important customers, and those risks and uncertainties described in our annual report on Form 10-K for the year ended December 31, 2006 filed with the Securities and Exchange Commission, our quarterly reports on Form 10-Q and other filings made by us with the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.
CONTACT: Paul Voegelin of Interleukin Genetics, +1-781-398-0700; or
Media-Investors, Erin Duggan of Weber Shandwick, +1-212-445-8238, or Rich
Tauberman of Financial Relations Board, +1-201-964-2408, both for
Interleukin Genetics
Web site: http://www.ilgenetics.com//
